Compare Stocks: BOLD, BCYC, AKBA, and CUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.93 -4.8%	$1.04	$0.81 ▼ $3.20	$271.56M	0.19	8.36 million shs	5.38 million shs
BCYC Bicycle Therapeutics	$3.60 -3.5%	$4.04	$3.57 ▼ $9.16	$261.07M	1.54	377,646 shs	374,248 shs
BOLD Boundless Bio	$2.70 -6.3%	$2.75	$0.96 ▼ $3.16	$65.51M	-0.03	88,570 shs	170,119 shs
CUE Cue Biopharma	$31.71 +2.6%	$29.22	$4.97 ▼ $45.50	$224.47M	2.45	381,012 shs	693,945 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+4.42%	+8.53%	+8.10%	-7.55%	-64.87%
BCYC Bicycle Therapeutics	+2.75%	+1.63%	-14.65%	-5.81%	-47.69%
BOLD Boundless Bio	+1.77%	+2.49%	-4.00%	+10.77%	+155.32%
CUE Cue Biopharma	+9.30%	-2.34%	+28.86%	+18.80%	-95.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.93 -4.8%	$1.04	$0.81 ▼ $3.20	$271.56M	0.19	8.36 million shs	5.38 million shs
BCYC Bicycle Therapeutics	$3.60 -3.5%	$4.04	$3.57 ▼ $9.16	$261.07M	1.54	377,646 shs	374,248 shs
BOLD Boundless Bio	$2.70 -6.3%	$2.75	$0.96 ▼ $3.16	$65.51M	-0.03	88,570 shs	170,119 shs
CUE Cue Biopharma	$31.71 +2.6%	$29.22	$4.97 ▼ $45.50	$224.47M	2.45	381,012 shs	693,945 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+4.42%	+8.53%	+8.10%	-7.55%	-64.87%
BCYC Bicycle Therapeutics	+2.75%	+1.63%	-14.65%	-5.81%	-47.69%
BOLD Boundless Bio	+1.77%	+2.49%	-4.00%	+10.77%	+155.32%
CUE Cue Biopharma	+9.30%	-2.34%	+28.86%	+18.80%	-95.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.43	Hold	$3.90	318.19% Upside
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	284.92% Upside
BOLD Boundless Bio	1.00	Sell	N/A	N/A
CUE Cue Biopharma	2.00	Hold	$83.00	161.75% Upside

Current Analyst Ratings Breakdown

Latest BOLD, BCYC, AKBA, and CUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	CUE Cue Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$83.00
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$83.00
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.50
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.09	N/A	N/A	$0.12 per share	7.77
BCYC Bicycle Therapeutics	$61.21M	4.12	N/A	N/A	$8.79 per share	0.41
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$4.41 per share	N/A
CUE Cue Biopharma	$37.66M	6.12	N/A	N/A	$10.08 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
BOLD Boundless Bio	-$58.20M	-$2.86	N/A	N/A	N/A	N/A	-70.89%	-47.37%	N/A
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	11/11/2026 (Estimated)

Latest BOLD, BCYC, AKBA, and CUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/7/2026	Q2 2026	BOLD Boundless Bio	N/A	-$1.06	N/A	-$1.06	N/A	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
BCYC Bicycle Therapeutics	N/A	12.08	12.08
BOLD Boundless Bio	N/A	9.48	9.48
CUE Cue Biopharma	N/A	1.25	1.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
BCYC Bicycle Therapeutics	86.15%
BOLD Boundless Bio	N/A
CUE Cue Biopharma	35.04%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
BCYC Bicycle Therapeutics	22.00%
BOLD Boundless Bio	23.10%
CUE Cue Biopharma	14.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	194	277.11 million	265.19 million	Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
BOLD Boundless Bio	28	22.75 million	17.49 million	No Data
CUE Cue Biopharma	29	7.26 million	6.21 million	Optionable

BOLD, BCYC, AKBA, and CUE Headlines

Recent News About These Companies

Die Cue-Biopharma-Aktie fällt nach CUE-221-Daten deutlich

2 hours ago | ad-hoc-news.deA

Cue Biopharma (NASDAQ:CUE) Raised to Hold at Zacks Research

September 23 at 6:05 AM | marketbeat.com

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

September 22 at 5:52 PM | biopharmadive.comB

Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking

September 22 at 7:51 AM | ad-hoc-news.deA

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

September 21 at 6:00 PM | seekingalpha.com

Cue chalks up phase 2 hives win for Xolair challenger

September 21 at 2:58 PM | fiercebiotech.comF

Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate

September 21 at 2:58 PM | finance.yahoo.com

Cue Biopharma rises after CUE-221 results

September 21 at 2:58 PM | grafa.comG

Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results

September 21 at 2:58 PM | finance.yahoo.com

Cue Biopharma Shares Jump With Positive Results in Chronic Spontaneous Urticaria Trial

September 21 at 2:58 PM | marketwatch.com

Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset

September 21 at 2:58 PM | msn.com

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript

September 21 at 12:00 PM | seekingalpha.com

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic ...

September 20 at 11:24 PM | enidnews.comE

Cue Biopharma's CUE-221 Meets Phase 2 Goals In Chronic Hives Study; Stock Up

September 20 at 11:24 PM | rttnews.com

Cue Biopharma's CUE-221 meets endpoints in phase 2 hives trial

September 20 at 7:53 AM | streetinsider.com

Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria

September 20 at 6:11 AM | quiverquant.comQ

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

September 20 at 6:00 AM | globenewswire.com

B. Riley Financial Begins Coverage on Cue Biopharma (NASDAQ:CUE)

September 20 at 1:48 AM | americanbankingnews.com

Cue Biopharma is a new buy at B Riley on valuation

September 19, 2026 | msn.com

B Riley Securities initiates coverage of Cue Biopharma with buy

September 18, 2026 | msn.com

Cue Biopharma is a new Buy at B. Riley on valuation

September 18, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BOLD, BCYC, AKBA, and CUE Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.93 -0.05 (-4.84%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 +0.00 (+0.04%)

As of 07:48 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bicycle Therapeutics NASDAQ:BCYC

$3.60 -0.13 (-3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$3.60 0.00 (-0.14%)

As of 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Boundless Bio NASDAQ:BOLD

$2.70 -0.18 (-6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$2.72 +0.01 (+0.56%)

As of 07:30 PM Eastern

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Cue Biopharma NASDAQ:CUE

$31.71 +0.81 (+2.62%)

Closing price 04:00 PM Eastern

Extended Trading

$32.00 +0.29 (+0.91%)

As of 07:37 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLD, BCYC, AKBA, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLD, BCYC, AKBA, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLD, BCYC, AKBA, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLD, BCYC, AKBA, and CUE Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Bicycle Therapeutics NASDAQ:BCYC

Boundless Bio NASDAQ:BOLD

Cue Biopharma NASDAQ:CUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLD, BCYC, AKBA, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLD, BCYC, AKBA, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLD, BCYC, AKBA, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLD, BCYC, AKBA, and CUE Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Bicycle Therapeutics NASDAQ:BCYC

Boundless Bio NASDAQ:BOLD

Cue Biopharma NASDAQ:CUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools